| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pertuzumab |
| Brand | Perjeta® |
| Indication | The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. |
| Assessment Process | |
| Rapid review commissioned | 14/01/2013 |
| Rapid review completed | 31/01/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 02/05/2013 |
| NCPE assessment completed | 28/08/2013 |
| NCPE assessment outcome | Reimbursement not recommended |
The NCPE believes that pertuzumab in combination with trastuzumab and docetaxel is not a cost-effective treatment for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.
